...of the pharma's injectables business with the successful acquisition of Hospira Inc. in 2015 and InnoPharma Inc....

...market a generic version of Restasis. InnoPharma was acquired by Pfizer Inc. (NYSE:PFE) in 2014. InnoPharma...
...or earlier "under certain circumstances." Allergan also said that "under certain circumstances," Allergan will supply InnoPharma...

...market a generic version of Restasis. InnoPharma was acquired by Pfizer Inc. (NYSE:PFE) in 2014. InnoPharma...
...or earlier "under certain circumstances." Allergan also said that "under certain circumstances," Allergan will supply InnoPharma...

...million in cash. InnoPharma is eligible for up to $135 million in milestones. Sales for InnoPharma...

...InnoPharma is also eligible for up to $135 million in milestones (see BioCentury, July 21). InnoPharma Inc....

...in cash up front. InnoPharma is also eligible for up to $135 million in milestones. InnoPharma...
...73 products. The company’s injectables portfolio is part of its Global Established Pharma business. The InnoPharma...
...Pfizer. JPMorgan was financial advisor and Morgan, Lewis & Bockius LLP was legal advisor to InnoPharma...

...in cash up front. InnoPharma is also eligible for up to $135 million in milestones. InnoPharma...
...company was bidding to acquire AstraZeneca plc (LSE:AZN; NYSE:AZN) (see BioCentury, May 12) . The InnoPharma...

...InnoPharma secured a $20 million term loan facility from Athyrium Capital Management. InnoPharma Inc. , Piscataway, N.J...

...of the approval, InnoPharma received 180-day exclusivity for the generic. Fresenius Kabi has rights from InnoPharma...
...Pharmaceuticals Inc. (NASDAQ:CPIX), Nashville, Tenn. Fresenius SE & Co. KGaA (Xetra:FRE; OTCBB:FSNUY), Bad Homburg, Germany InnoPharma Inc....